ETFs & Funds
Home›ETFs & Funds›Equity Funds›Lilly raises outlook for third time this year as Zepbo…
Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues do dominate the market for prescription weight-loss drugs in the U.S.
← Newer storyPutin praises Elon Musk as a ‘genius’ as Russia develops Starlink alt…Older story →Bitcoin Has Failed to Break Through Resistance, Whereas Bnb Is Gainin…